Italian drugmaker Angelini Pharma is working with advisers as it studies a potential acquisition of Catalyst Pharmaceuticals (CPRX), people familiar with the matter told Bloomberg’s Manuel Baigorri, Dinesh Nair, and Daniele Lepido. Discussions are at a preliminary stage, according to the sources, the report added. Catalyst shares closed nearly 7% higher at $29.27 following the report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals trading resumes
- Catalyst Pharmaceuticals trading halted, volatility trading pause
- Catalyst Pharma Patent Trial Against Hetero USA Delayed
- Catalyst Pharmaceutical Partners Signals Confident Growth Path
- Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside